Literature DB >> 17196217

Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples.

Emma Lundberg1, Ingmarie Höidén-Guthenberg, Barbro Larsson, Mathias Uhlén, Torbjörn Gräslund.   

Abstract

Affibody molecules are a class of small and robust affinity proteins that can be generated to interact with a variety of antigens, thus having the potential to provide useful tools for biotechnological research and diagnostic applications. In this study, we have investigated Affibody-based reagents interacting specifically with the tyrosine kinase receptor HER2. A head-to-tail dimeric construct was site-specifically conjugated with different fluorescent and enzymatic groups resulting in reagents that were used for detection and quantification. The amount of cell surface expressed HER2 on eleven (11) well characterized cell lines was quantified relative to each other by flow cytometry and shown to correlate well with results from parallel analyses of HER2 mRNA levels measured by real-time PCR. Further, immunofluorescence microscopy studies of the cell lines and immunohistochemical analyses of cryosections of HER2 expressing SKOV-3 xenografts showed strong staining of the plasma membrane of tumor cells with little background staining. Full-length HER2 protein could also be efficiently recovered from a cell extract by an immunoprecipitation procedure, using an Affibody ligand-based resin. These novel non-IgG derived reagents could be used to detect and quantify HER2 expression. By adapting the methods for use with Affibody molecules binding to other cell surface receptors, it is anticipated that also these receptors can be detected and quantified in a similar manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196217     DOI: 10.1016/j.jim.2006.10.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

Review 1.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

2.  Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.

Authors:  Vladimir Tolmachev; Heng Xu; Helena Wållberg; Sara Ahlgren; Magnus Hjertman; Anna Sjöberg; Mattias Sandström; Lars Abrahmsén; Martin W Brechbiel; Anna Orlova
Journal:  Bioconjug Chem       Date:  2008-07-12       Impact factor: 4.774

3.  In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging.

Authors:  Moinuddin Hassan; Victor Chernomordik; Rafal Zielinski; Yasaman Ardeshirpour; Jacek Capala; Amir Gandjbakhche
Journal:  Mol Imaging       Date:  2012-06       Impact factor: 4.488

4.  Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease.

Authors:  Matthias Vandesquille; Tengfei Li; Chrystelle Po; Christelle Ganneau; Pascal Lenormand; Clémence Dudeffant; Christian Czech; Fiona Grueninger; Charles Duyckaerts; Benoît Delatour; Marc Dhenain; Pierre Lafaye; Sylvie Bay
Journal:  MAbs       Date:  2017-06-28       Impact factor: 5.857

5.  Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

Authors:  Vladimir Tolmachev; Helena Wållberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

6.  HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Authors:  Ilya Lyakhov; Rafal Zielinski; Monika Kuban; Gabriela Kramer-Marek; Robert Fisher; Oleg Chertov; Lakshman Bindu; Jacek Capala
Journal:  Chembiochem       Date:  2010-02-15       Impact factor: 3.164

7.  SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression.

Authors:  Lieven Huang; Lea Olive Tchouate Gainkam; Vicky Caveliers; Chris Vanhove; Marleen Keyaerts; Patrick De Baetselier; Axel Bossuyt; Hilde Revets; Tony Lahoutte
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

8.  The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.

Authors:  Vladimir Tolmachev; Helena Wållberg; Karl Andersson; Anders Wennborg; Hans Lundqvist; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-09       Impact factor: 9.236

9.  [99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.

Authors:  Anna Orlova; Camilla Hofström; Joanna Strand; Zohreh Varasteh; Mattias Sandstrom; Karl Andersson; Vladimir Tolmachev; Torbjörn Gräslund
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-21       Impact factor: 9.236

10.  Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.

Authors:  Sang Bong Lee; Moinuddin Hassan; Robert Fisher; Oleg Chertov; Victor Chernomordik; Gabriela Kramer-Marek; Amir Gandjbakhche; Jacek Capala
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.